Sort   by:  
 Page size 
UnknownDual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.
Not available
S-EPMC3880137 | biostudies-literature
UnknownSafety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.
Not available
S-EPMC3963491 | biostudies-literature
TranscriptomicsExpression profiling of breast cancer cell lines MCF-7 and MCF-7R4
Human breast cancer cell line MCF-7 is usually sensitive to chemotherapy drug BMS-554417, an insulin receptor (IR) and insulin-like growth factor receptor (IGFR) inhibitor. However, through step-wise increase in BMS-554417 doses in culture media, we were able able to screen and select a single MCF-7...
ORGANISM(S): Homo sapiens 
2009-11-05 | E-GEOD-18912 | biostudies-arrayexpress
TranscriptomicsRidaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
Introduction: Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ER...
ORGANISM(S): Homo sapiens 
2016-07-01 | E-GEOD-79492 | biostudies-arrayexpress
TranscriptomicsExpression data from MCF7 tumor xenografts treated with either single agent BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days
breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor ef...
ORGANISM(S): Homo sapiens 
2011-11-02 | E-GEOD-33366 | biostudies-arrayexpress
Sort   by:  
 Page size